Skip to content
Matrix Global Advisors
Matrix Global Advisors
  • Home
  • About
  • News
  • Our Work
  • Contact
  • Home
  • About
  • News
  • Our Work
  • Contact
Sep62018
Analysis

New MGA Paper Identifies Steps to Reducing Barriers to Biosimilars

In a new paper, MGA discusses why the biosimilars market in the United States is not more developed and what steps can be taken to boost competition for biologic drugs. The paper identifies barriers to biosimilars by four categories, related to reference product manufacturers, biosimilar manufacturers, policy, and stakeholder education and awareness. Among the strategies to overcoming barriers are more physician and patient education, competitive biosimilar pricing, action by employer-sponsored health plans and private payors to encourage biosimilar utilization, and continued FDA efforts to support the budding market.

Read Here

September 6, 2018Category: Analysis

Post navigation

PreviousPrevious post:Alex Brill Presents at GRx+Biosims 2018 ConferenceNextNext post:New MGA Study Estimates Lost Savings from Misuse of REMS and Restricted Access Programs
  • Analysis(29)
  • Books(2)
  • Events(13)
  • Interviews(37)
  • News(46)
  • Op-Eds(63)
  • Press Releases(2)
  • Testimony(19)
  • Alex Brill Talks Trade Disruption Due to Suez Canal Blockage on i24 News
    March 31, 2021
  • Alex Brill Featured in Foundation for Economic Education Article
    March 26, 2021
  • U.S. Spending and Tax Policy After the COVID Recessions: Political Economy Podcast
    March 24, 2021
  • Alex Brill Testifies Before U.S. Senate on Lowering Prescription Drug Prices
    March 23, 2021

Website Design and Developed by DreamBig Creative